A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Trial ID or NCT#

NCT01306890

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.

Official Title

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: MALE
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * subjects must be at least 18 years of age* subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to enrollment* subjects must understand and sign an informed consent form
Exclusion Criteria:
  1. * none
View All Criteria
Show Less

Investigator(s)

Sandy Srinivas
Sandy Srinivas
Medical oncologist, Urologic specialist, Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology

Contact us to find out if this trial is right for you.

Contact

Denise Haas
6507361252

View on ClinicalTrials.gov